|
|
 |
|
Viewing report
|
|
|
|
Netherlands Pharmaceuticals and Healthcare Report Q3 2008
Business Monitor International, Sep 2008, Pages: 74
BMI's Netherlands Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Netherlands's pharmaceuticals and healthcare industry.
The most significant event in the Netherlands Pharmaceutical industry this quarter was the introduction of a preferential price policy for generic medicines. Taking effect on June 1 2008, health insurers will only reimburse the cheapest of 36 commonly used drugs. The closed bidding system is likely to cause a significant reduction in medicines prices and therefore will have a severe impact on the generics market, particularly if insurers fully implement the pricing policy. At present, It is set to cover half of the market. The policy has come as a result of the Pharmaceutical Care Transition Agreement 2008/2009 which in Q108 had already led to a 10% reduction in generics prices and up to 50% of medicines with patent expiries pending. Price drops are likely to have financial impacts for companies throughout the supply chain, from manufacturers through to pharmacies.
Other significant events include the publication of a report in May 2008 that highlighted a rapid increase in the number of people defaulting on health insurance; up 26% in 2007. This is a worrying sign for the drug market as shortfalls it will likely lead to shortfalls in health budgets and also represents the large financial debts people have will which possibly affect over-the-counter (OTC) drug spending. On a more positive note the number of people with no health insurance has decreased by 10,000 to 231,000. In April 2008 the Dutch government announced that the cost of premium treatments will no longer be tax deductible from January 2009. At present, taxpayers can deduct costs of high-price pharmaceuticals that are not being covered by their health insurance if they exceed a certain proportion of an individual’s salary.
BMI’s Burden of Disease Database (BoDD) has shown the Netherlands to be the 7th least disease burdened country in Western Europe. Neuropsychiatric conditions, cancer and cardiovascular diseases are the diseases to be the most burdensome in the country, a statistic set to stay that way for the full forecast period until 2030.
In a positive move for cancer prevention, the Dutch Health Council recommended that human papillomavirus vaccinations be included in the national immunisation programme. This is likely to lead to a battle between GlaxoSmithKline and Sanofi-Pasteur MSD to establish their vaccines as the number one preference.
Company-wise there was plenty of activity for local players. The highlights included DSM acquiring Polymer Technology Group (PTG) and posting impressive sales growth, while wholesaler OPG announced plans to expand into Poland. In addition, nine research projects in the Netherlands are set to receive EUR150mn from the Centre for Translational Molecular Medicine (CTMM) in an attempt to improve knowledge of disease development.
Also available
Netherlands Pharmaceuticals & Healthcare Report Q1 2008
Netherlands Pharmaceuticals & Healthcare Report Q1 2008
Netherlands Pharmaceuticals and Healthcare Report Q2 2008
Netherlands Pharmaceuticals and Healthcare Report Q2 2008
Netherlands Pharmaceuticals and Healthcare Report Q4 2008
Customers who bought this item also bought
Netherlands Pharmaceuticals and Healthcare Report Q4 2008
Netherlands Pharmaceuticals and Healthcare Report Q2 2008
Netherlands Pharmaceuticals & Healthcare Report Q1 2008
The Pharmaceutical Market: Netherlands
South Africa Pharmaceuticals and Healthcare Report Q3 2008
United Arab Emirates Pharmaceuticals and Healthcare Report Q4 2008
Egypt Pharmaceuticals and Healthcare Report Q1 2009
Netherlands Pharmaceuticals and Healthcare Report Q1 2009
South Africa Pharmaceuticals and Healthcare Report Q4 2008
Philippines Pharmaceuticals and Healthcare Report Q3 2008
Bahrain Pharmaceuticals and Healthcare Report Q3 2008
Estonia Pharmaceuticals and Healthcare Report Q4 2009
|
|
|
|
